[The use of prasugrel in STEMI and NSTEMI: TRITON TIMI 38 study and subgroup analyses]

Turk Kardiyol Dern Ars. 2015 Oct;43 Suppl 2:1-6.
[Article in Turkish]

Abstract

Prasugrel, a third generation P2Y12 receptor inhibitor, is more powerful than clopidogrel. TRITON-TIMI 38 trial compared the effectiveness of prasugrel with clopidogrel in patients with STEMI and NSTEMI. This paper examined the main TRITON-TIMI 38 trial and subgroup analyses of the trial to determine patient subgroups in which prasugrel is superior to clopidogrel in preventing clinical events without an additional increase in bleeding risk. In such patients, one might expect to derive optimal benefit from prasugrel without a significant increase in bleeding.

Publication types

  • Clinical Trial, Phase III
  • Randomized Controlled Trial

MeSH terms

  • Acute Coronary Syndrome / drug therapy*
  • Clopidogrel
  • Humans
  • Myocardial Infarction / drug therapy*
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Prasugrel Hydrochloride / therapeutic use*
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / therapeutic use
  • Treatment Outcome

Substances

  • Platelet Aggregation Inhibitors
  • Clopidogrel
  • Prasugrel Hydrochloride
  • Ticlopidine